Biopharmaceuticals Market Size, Share, and Growth Analysis, By Type (Immunomodulators, Enzymes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), By Application, By Region - Industry Forecast 2025-2032
바이오의약품 시장 규모는 2023년 5,703억 달러로 평가되었습니다. 또한, 2024년 6,085억 1,000만 달러에서 2032년에는 1조 223억 1,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 연평균 6.7%의 성장률을 보일 것으로 예상됩니다.
시장 인사이트에 따르면, 바이오 의약품에 대한 수요는 세계 인구 증가와 노화 관련 질병 및 만성 질환 증가와 함께 확대되고 있습니다. 세계보건기구(WHO)는 2020년에는 65세 이상 성인이 5세 미만 어린이보다 많을 것이며, 이 추세는 2050년까지 비슷해질 것으로 예측했습니다. 이러한 인구통계학적 변화로 인해 암, 신경질환, 심혈관질환 등 노인에게 많이 발생하는 질병을 관리하기 위한 헬스케어 서비스에 대한 수요가 증가하고 있습니다. 가족 간병과 전문 간병에 대한 수요 증가는 이러한 수요를 더욱 증폭시키고, 바이오제약 기업의 연구개발 투자를 촉진하고 있습니다. 또한, 바이오 의약품에 대한 규제 당국의 승인 증가는 혁신적인 치료법에 대한 신속한 접근을 약속하며 향후 몇 년동안 시장 성장을 크게 촉진할 것입니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장 전제조건과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 Five Forces 분석
주요 시장 인사이트
- 중요 성공 요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 상황
- 사례 연구
- 기술 진보
바이오의약품 시장 규모 : 유형별&CAGR(2025-2032년)
- 시장 개요
- 면역조절제
- 효소
- Hyrdolases
- Lyases
- 산화 환원 효소
- 기타
- 백신
- 재조합/접합/서브유닛
- 비활성화
- 생약독화
- 톡소이드
- 호르몬
- 인간 성장 호르몬
- 인슐린
- 갑상선 자극 호르몬
- 기타
- 기타
바이오의약품 시장 규모 : 유통 채널별&CAGR(2025-2032년)
- 시장 개요
- 병원 약국
- 드럭스토어 및 약국
- 온라인 약국
바이오의약품 시장 규모 : 용도별&CAGR(2025-2032년)
- 시장 개요
- 심장병학
- 종양학
- 호흡기
- 면역학
- 신경학
- 기타
바이오의약품 시장 규모&CAGR(2025-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 주요 5개사 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 상세
- 제품 포트폴리오 분석
- 기업 부문별 점유율 분석
- 매출 전년대비 비교(2022-2024년)
주요 기업 개요
- Lonza Group(Switzerland)
- WuXi Biologics(China)
- Fujifilm Diosynth Biotechnologies(Japan)
- Recipharm(Sweden)
- Samsung Biologics(South Korea)
- Boehringer Ingelheim(Germany)
- Catalent(USA)
- Thermo Fisher Scientific(USA)
- Siegfried Holding AG(Switzerland)
- AGC Biologics(Japan)
- WuXi AppTec(China)
- Cambrex Corporation(USA)
- Charles River Laboratories(USA)
- Chugai Pharmaceutical(Japan)
- Biocon Limited(India)
- Dr. Reddy's Laboratories(India)
- Sun Pharmaceutical Industries(India)
- Teva Pharmaceutical Industries(Israel)
- Novartis(Switzerland)
결론과 제안
LSH
Biopharmaceuticals Market size was valued at USD 570.3 billion in 2023 and is poised to grow from USD 608.51 billion in 2024 to USD 1022.31 billion by 2032, growing at a CAGR of 6.7% during the forecast period (2025-2032).
Market insights reveal a growing demand for biopharmaceuticals, driven by an increasing global population coupled with a rise in age-related diseases and chronic medical conditions. The World Health Organization notes that in 2020, adults aged 65 and older outnumbered children under five, a trend expected to equalize by 2050. This demographic shift is prompting heightened demand for healthcare services, particularly to manage disorders like cancer, neurological conditions, and cardiovascular diseases prevalent among seniors. The rising need for both family and professional care further amplifies this demand, encouraging biopharmaceutical companies to boost investments in research and development. Additionally, an uptick in regulatory approvals for biopharmaceutical products promises expedited access to innovative treatments, significantly propelling the market's growth in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the Biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Biopharmaceuticals Market Segments Analysis
Global Biopharmaceuticals Market is segmented by Type, Distribution Channel, Application and region. Based on Type, the market is segmented into Immunomodulators, Enzymes, Vaccines, Hormones and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on Application, the market is segmented into Cardiology, Oncology, Respiratory, Immunology, Neurology and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Biopharmaceuticals Market
A significant driver fueling the growth of the biopharmaceuticals market is the escalating prevalence of chronic diseases worldwide. This alarming rise has prompted governments across various regions to initiate awareness campaigns aimed at educating the public about these conditions, resulting in a heightened focus on treatment options. Consequently, the demand for medications in the biopharmaceutical sector, particularly those targeting specialized areas such as rare, chronic, and hereditary disorders, is expected to see a steady increase. As more individuals become aware of their healthcare options, the market is poised for substantial expansion, driven by the need for effective therapeutic solutions.
Restraints in the Biopharmaceuticals Market
The biopharmaceuticals market faces significant restraints due to the elevated costs associated with development and production. The complex manufacturing processes and stringent regulatory requirements necessitate advanced technologies, resulting in the higher overall expense of biologics. This inflated cost can create barriers to access and limit affordability for numerous patients and healthcare systems. Consequently, the financial challenges linked to the development and formulation of biopharmaceuticals mean that many individuals may not benefit from these innovative therapies, ultimately hindering the market's growth and restricting patient access to essential treatments.
Market Trends of the Biopharmaceuticals Market
The biopharmaceutical market is witnessing a transformative trend in gene and cell therapies, which address pressing healthcare needs, particularly for rare diseases, cancers, and genetic disorders. These innovative therapies are ushering in a new era of personalized medicine, offering potential curative solutions through targeted cell or DNA replacement. The efficacy of these treatments is bolstered by breakthroughs in viral vector delivery systems and CRISPR technology, enhancing precision and outcomes. However, challenges related to high costs and navigating regulatory approvals remain prominent. As research and development efforts continue, the market is anticipated to expand significantly, revolutionizing patient care and treatment paradigms.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Landscape
- Case Studies
- Technological Advancement
Global Biopharmaceuticals Market Size by Type & CAGR (2025-2032)
- Market Overview
- Immunomodulators
- Monoclonal Antibodies
- Cytokines
- Interferons
- Others
- Enzymes
- Hyrdolases
- Lyases
- Oxidoreductases
- Others
- Vaccines
- Recombinant/Conjugate/Subunit
- Inactivated
- Live Attenuated
- Toxoid
- Hormones
- Human Growth Hormones
- Insulin
- Thyroid Stimulating Hormones
- Others
- Others
Global Biopharmaceuticals Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Global Biopharmaceuticals Market Size by Application & CAGR (2025-2032)
- Market Overview
- Cardiology
- Oncology
- Respiratory
- Immunology
- Neurology
- Others
Global Biopharmaceuticals Market Size & CAGR (2025-2032)
- North America (Type, Distribution Channel, Application)
- Europe (Type, Distribution Channel, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Distribution Channel, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Distribution Channel, Application)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Distribution Channel, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Recipharm (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siegfried Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AGC Biologics (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cambrex Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chugai Pharmaceutical (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
